Skip to Content
Merck

Anxiolytic effects of Formononetin in an inflammatory pain mouse model.

Molecular brain (2019-04-10)
Xin-Shang Wang, Shao-Yu Guan, An Liu, Jiao Yue, Li-Ning Hu, Kun Zhang, Liu-Kun Yang, Liang Lu, Zhen Tian, Ming-Gao Zhao, Shui-Bing Liu
ABSTRACT

Chronic pain is commonly accompanied with anxiety disorder, which complicates treatment. In this study, we investigated the analgesic and anxiolytic effects of Formononetin (FMNT), an active component of traditional Chinese medicine red clover (Trifolium pratense L.) that is capable of protecting neurons from N-methyl-D-aspartate (NMDA)-evoked excitotoxic injury, on mice suffering from complete Freund's adjuvant (CFA)-induced chronic inflammatory pain. The results show that FMNT administration significantly reduces anxiety-like behavior but does not affect the nociceptive threshold in CFA-injected mice. The treatment reverses the upregulation of NMDA, GluA1, and GABAA receptors, as well as PSD95 and CREB in the basolateral amygdala (BLA). The effects of FMNT on NMDA receptors and CREB binding protein (CBP) were further confirmed by the potential structure combination between these compounds, which was analyzed by in silico docking technology. FMNT also inhibits the activation of the NF-κB signaling pathway and microglia in the BLA of mice suffering from chronic inflammatory pain. Therefore, the anxiolytic effects of FMNT are partially due to the attenuation of inflammation and neuronal hyperexcitability through the inhibition of NMDA receptor and CBP in the BLA.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-β-Actin antibody produced in mouse, clone AC-74, ascites fluid
Sigma-Aldrich
Anti-NMDAR2A Antibody, serum, Chemicon®
Sigma-Aldrich
Anti-Glutamate Receptor 1 Antibody, phosphoSer 845, Chemicon®, from rabbit
Sigma-Aldrich
Anti-Glutamate Receptor 1 Antibody, phosphoSer 831, Chemicon®, from rabbit